amgen (amgn) gains as market dips: what you should know. in the latest trading session amgen (amgn) closed at $238.48 marking a 0.73% move from the previous day. the stock outpaced the s&.p 500s daily loss of 0.16%. meanwhile the do

United States supreme court hears amgen bid to revive cholesterol drug patents. the United States supreme court on monday began hearing a bid by amgen inc to revive patents on its cholesterol-lowering drug repatha in a legal effort that rival sa

amgen bid to revive cholesterol drug patents comes to United States supreme court. the United States supreme court on monday is set to hear a bid by amgen inc to revive patents on its cholesterol-lowering drug repatha in a legal effort that riva

amgen: revenue growth potentials and financial performance.

heres what is driving amgen (amgn) stocks outperformance. amgen amgn is one of the biggest biotech companies in the world with a strong presence in the oncology/hematology cardiovascular disease neuroscience inflammation bone health an

amgen announces more layoffs - why id buy this dip.

looking at amgens recent unusual options activity. a whale with a lot of money to spend has taken a noticeably bearish stance on looking at options history for amgen (nasdaq:) we detected 15 strange trades. if we consider the specifics of each trade it

more United States companies layoff as amgen deepens job cuts amid pressure on drug prices and inflation woes.

amgen to cut 450 jobs in second round of layoffs this year. amgen inc said on thursday it would cut 450 jobs or less than 2% of its workforce making it the companys second round of layoffs this year amid intensifying pressure on drug prices and

dow movers: axp amgn. in early trading on monday shares of amgen topped the list of the days best performing dow jones industrial average components trading up 2.9%. year to date amgen inc has lost about 10.7% of its value.

hefty listing price of new drugs for cancer rare diseases put pressure on annual hike for older drugs. new branded medicines are coming to market with ever-higher price tags as soon as the first day.amgen inc'.s(nasdaq:amgn) lung cancer treatment lumak

amgen inc. (amgn) presents at 43rd annual td cowen healthcare conference (transcript).

death cross looms over amgen investors. if history is any guide there may be trouble ahead for shares of ). a so-called death cross has formed on its chart and not surprisingly this could be bearish for the stock. when a shorter-term average price cro

dow movers: crm amgn. in early trading on friday shares of amgen topped the list of the days best performing dow jones industrial average components trading up 1.4%. year to date amgen has lost about 9.6% of its value.

nasdaq 100 movers: mrna amgn. in early trading on friday shares of amgen topped the list of the days best performing components of the nasdaq 100 index trading up 1.6%. year to date amgen has lost about 9.4% of its value.

amgen enters oversold territory. the dividendrank formula at dividend channel ranks a coverage universe of thousands of dividend stocks according to a proprietary formula designed to identify those stocks that combine two important character

amgen nearing buy point with great dividend and fundamentals. amgen inc. (nasdaq: ) is right near the bottom of a more than 6-year trend channel. that presents a potentially good buy point. the stock also has a long history of strong fundamentals. theref

$1000 invested in amgen 15 years ago would be worth this much today. amgen (nasdaq:) has outperformed the market over the past 15 years by 3.9% on an annualized basis producing an average annual return of 11.57%. currently amgen has a market capitalizatio

hexagon bio raises $77.3 million series b financing and strengthens leadership to expand novel computational discovery platform and advance microbial genome-derived small molecules. hexagon'.s interdisciplinary platform enables broad opportunities a

amgen: price crash spells opportunity.

notable thursday option activity: amgn gm ccl. among the underlying components of the s&.p 500 index we saw noteworthy options trading volume today in amgen inc (symbol: amgn) where a total of 13617 contracts have traded so far representi

amgen (amgn) beats on q4 earnings 2023 sales view disappoints. amgen amgn reported fourth-quarter 2022 earnings of $4.09 per share which beat the zacks consensus estimate of $4.04. earnings declined 7% year over year due to a lower ope

: amgen stock falls 3.6% after q4 results late tuesday shaves 59 pts off the dows price. this is a real-time headline. these are breaking news delivered the minute it happens delivered ticker-tape style. visit www.marketwatch.com or the e page for more in

amgen revenue falls slightly as lilly covid deal contributes less. amgen inc on tuesday said its fourth-quarter revenue fell slightly as a 4% increase in sales of its own drugs was offset by lower revenue from its deal to manufacture covid-19 an

amgen lays off 300 employees mostly on commercial team - endpoints news.

drugmaker amgen lays off 300 United States employees. drugmaker amgen inc said on monday that it let go about 300 United States employees or about 1.2% of its total workforce citing recent organizational changes to its commercial team.

earnings preview: amgen. ) is set to give its latest quarterly earnings report on tuesday 2023-01-31. here'.s what investors need to know before the announcement. analysts estimate that amgen will report an amgen s will hope to hear the company ann

amgen pt lowered to $260 at ubs.

amgen is oversold. the dividendrank formula at dividend channel ranks a coverage universe of thousands of dividend stocks according to a proprietary formula designed to identify those stocks that combine two important characteristics &mdash.